Cervical cancer nursing: complete NCLEX reference

Cervical cancer is the fourth most common cancer in women worldwide and one of the most preventable — yet it remains a leading cause of cancer mortality in countries without established screening programs. In the United States, approximately 13,000 new cases are diagnosed annually, with the steepest disparities falling along lines of income, geography, and access to screening. For nursing students and NCLEX candidates, cervical cancer is high-yield territory: it covers HPV biology, primary prevention through vaccination, multi-decade screening protocols, FIGO staging, concurrent chemoradiation, and a distinctive set of post-treatment nursing priorities including radiation-induced vaginal stenosis and cisplatin nephrotoxicity.

What distinguishes cervical cancer from most solid tumors is that its etiology is almost fully understood. Human papillomavirus (HPV) is a necessary — though not sufficient — cause in virtually every case. That makes cervical cancer a disease where nursing can intervene at every level: vaccine counseling, screening education, post-diagnosis management, and survivorship care. The oncology cluster on this site starts with oncology nursing reference for chemotherapy safety frameworks and continues with the gyn-oncology cluster at ovarian cancer nursing.

Pathophysiology and HPV biology

Cervical cancer arises from the transformation zone of the cervix — the squamocolumnar junction where columnar endocervical epithelium meets stratified squamous ectocervical epithelium. This zone is biologically active, particularly during adolescence and pregnancy, and is where HPV infection takes hold most readily.

Human papillomavirus is a double-stranded DNA virus. Of the 200+ known HPV strains, roughly 15 are classified as high-risk oncogenic types. HPV 16 and 18 together account for approximately 70% of all cervical cancers. HPV 16 predominates in squamous cell carcinoma; HPV 18 is more strongly associated with adenocarcinoma. Low-risk types HPV 6 and 11 cause anogenital warts (condylomata acuminata) but carry no significant malignant potential.

After infecting basal epithelial cells, high-risk HPV integrates its genome into the host cell. Viral oncoproteins E6 and E7 then disable critical tumor suppressor proteins: E6 degrades p53 (which would otherwise trigger apoptosis), and E7 inactivates pRb (which normally halts the cell cycle). The result is unregulated proliferation, genomic instability, and eventual malignant transformation.

The progression from HPV infection to invasive cancer is not inevitable and is typically slow — often spanning 10–20 years. This extended window is exactly what makes cytologic screening effective.

CIN classification

Precancerous lesions are classified as cervical intraepithelial neoplasia (CIN):

• CIN 1: Mild dysplasia involving the lower third of the epithelium. Majority regress spontaneously. Corresponds to LSIL on cytology.
• CIN 2: Moderate dysplasia involving the lower two-thirds. Intermediate risk; some regress, some progress.
• CIN 3: Severe dysplasia or carcinoma in situ involving the full epithelial thickness. High risk of progression to invasion without treatment.

CIN 3 that breaks through the basement membrane becomes invasive cervical cancer. At that point, lymphovascular invasion and metastatic spread become possible.

Histologic types

Spread patterns

Cervical cancer spreads predictably. Local extension goes laterally into the parametrium and pelvic sidewall, anteriorly into the bladder, and posteriorly into the rectum. Lymphatic spread follows first to pelvic nodes (obturator, internal and external iliac), then to common iliac and para-aortic nodes. Involvement of para-aortic nodes dramatically worsens prognosis and shifts radiation fields. Hematogenous spread to lung, liver, and bone occurs in advanced disease.

Lymph node involvement was formally incorporated into FIGO staging in 2018 as Stage IIIC — a clinically significant update that NCLEX questions now reflect.

Risk factors and prevention

HPV infection is necessary but not sufficient for cervical cancer development. Co-factors influence whether infection persists and progresses.

HPV acquisition risk: Early sexual debut (before age 16), multiple lifetime sexual partners, and a partner with multiple partners all increase HPV exposure probability.

Immune status: Immunosuppression is a major modifier. HIV-positive women have significantly higher rates of HPV persistence, CIN, and cervical cancer — cervical cancer is an AIDS-defining illness. Solid organ transplant recipients and patients on long-term immunosuppressants carry similar elevated risk.

Smoking: Tobacco metabolites accumulate in cervical mucus and act as co-carcinogens. Smokers are roughly twice as likely to develop cervical cancer as non-smokers.

Other factors: Long-term combined oral contraceptive use (≥5 years) modestly increases risk; chlamydia co-infection is associated with persistence of HPV; low socioeconomic status correlates with reduced screening access and later-stage diagnosis.

HPV vaccination

Gardasil 9 is the only HPV vaccine used in the United States. It covers 9 strains: HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58. The six high-risk strains (16, 18, 31, 33, 45, 52, 58) collectively account for approximately 90% of HPV-attributable cervical cancers. HPV 6 and 11 coverage prevents genital warts.

Recommended schedule:

• Ages 9–14: 2-dose series (0 and 6–12 months)
• Ages 15–26: 3-dose series (0, 1–2, and 6 months)
• Ages 27–45: shared decision-making — benefit is lower because most adults have had prior HPV exposure

Critical nursing point: Gardasil 9 is prophylactic, not therapeutic. It prevents new HPV infection but does not clear existing infection or treat CIN. It must be administered before HPV exposure to confer protection. Completing the series after partial vaccination still provides benefit; however, an HPV-positive test result does not mean vaccination is contraindicated — it means some protection against other uncovered strains is still possible.

Cervical cancer screening

Screening has reduced cervical cancer mortality in the United States by over 70% since the Pap smear was introduced. Understanding current guidelines is high-yield for NCLEX.

Current USPSTF/ACOG recommendations

Pap smear cytology results and management

Liquid-based cytology (ThinPrep, SurePath) has largely replaced conventional smear methods. Results are classified using the Bethesda System:

• NILM (Negative for Intraepithelial Lesion or Malignancy): Normal result; return to routine screening.
• ASCUS (Atypical Squamous Cells of Undetermined Significance): The most common abnormal result. Management depends on HPV reflex testing. ASCUS + high-risk HPV positive → colposcopy. ASCUS + HPV negative → routine screening.
• LSIL (Low-grade Squamous Intraepithelial Lesion): Corresponds to CIN 1. In women 25–65, colposcopy is preferred. In women 21–24, colposcopy or one-year repeat is acceptable.
• HSIL (High-grade Squamous Intraepithelial Lesion): Corresponds to CIN 2–3. Colposcopy is indicated; immediate LEEP is an acceptable alternative in certain patients.
• ASC-H (Atypical Squamous Cells, Cannot Exclude HSIL): Colposcopy indicated.

Colposcopy is a direct visual examination of the cervix using a binocular magnifying scope and acetic acid (which highlights dysplastic epithelium as acetowhite areas). Abnormal areas are biopsied. Endocervical curettage (ECC) samples the canal. Results guide treatment decisions.

FIGO staging (2018)

The International Federation of Gynecology and Obstetrics revised the cervical cancer staging system in 2018. The most clinically significant update was the addition of Stage IIIC to incorporate lymph node status — previously a clinical staging system, FIGO 2018 now allows pathologic and imaging findings to upstage tumors.

Clinical presentation

Early-stage disease is typically asymptomatic — the most common route to diagnosis is an abnormal Pap result in an otherwise healthy woman. This is why screening compliance is the single most important modifiable factor in cervical cancer outcomes.

When symptoms do appear:

• Abnormal vaginal bleeding is the cardinal symptom. Postcoital bleeding (bleeding after intercourse) is particularly characteristic and should always prompt evaluation. Intermenstrual spotting and postmenopausal bleeding are also common presentations.
• Vaginal discharge may be watery, blood-tinged, or have a foul odor as the tumor undergoes necrosis.
• Pelvic pain emerges as disease extends to the parametrium or pelvic nerves.
• Advanced disease signs reflect local invasion: flank pain or decreased urine output from ureteral obstruction and hydronephrosis; lower extremity edema from lymphatic obstruction; sciatica-like radicular pain from lumbosacral nerve involvement; rectal bleeding or bowel symptoms from posterior extension.

Nurses in primary care settings are often the first clinician a patient mentions abnormal bleeding to. Normalizing postcoital bleeding as “just from friction” is a missed opportunity and a safety risk.

Diagnostics

Tissue confirmation is required for diagnosis. The sequence is: abnormal Pap → colposcopy → directed biopsy → pathologic diagnosis.

• Punch biopsy: Small tissue cores taken from acetowhite or abnormal areas visualized at colposcopy.
• ECC (endocervical curettage): Sampling of the endocervical canal, performed when the transformation zone is not fully visible or HSIL is present.
• LEEP (loop electrosurgical excision procedure): Excises the transformation zone using a wire loop. Both diagnostic (full specimen for margins) and therapeutic.
• Cold knife conization (CKC): Surgical cone biopsy under anesthesia; used for adenocarcinoma in situ (where margins matter more) and when LEEP is inadequate.

Staging workup after confirmed diagnosis:

• MRI pelvis: Best modality for assessing parametrial invasion, tumor size, and pelvic sidewall involvement.
• CT chest/abdomen/pelvis: Evaluates lymph nodes and distant spread.
• PET-CT: Increasingly standard for Stage IB2+ — superior sensitivity for nodal disease and distant metastases.
• Cystoscopy/sigmoidoscopy: Performed for Stage III–IV to confirm or exclude bladder/rectal invasion.
• SCC antigen (SCC-Ag): A serum marker elevated in squamous cell carcinoma. Not used for diagnosis (too nonspecific) but valuable for monitoring treatment response and detecting recurrence.

Treatment by stage

Precancerous lesions (CIN 2/3)

• LEEP: Outpatient procedure under local anesthesia. Most widely used. Margins assessable.
• Cold knife conization: Preferred for adenocarcinoma in situ or when LEEP margins are positive.
• Ablative therapies (cryotherapy, laser ablation): Acceptable for CIN 2/3 where colposcopy is satisfactory and ECC is negative; cannot be used if invasion cannot be excluded.

Early invasive disease (Stage IA1–IIA)

• Stage IA1 with no lymphovascular invasion: LEEP or simple hysterectomy if fertility not desired.
• Stage IA1 with LVSI, or Stage IA2–IB1 with fertility desire: Radical trachelectomy (removes cervix, preserves uterus) + pelvic lymph node dissection.
• Stage IB1–IIA: Radical hysterectomy with bilateral pelvic lymph node dissection (Wertheim procedure), OR concurrent chemoradiation — equivalent outcomes for IB1; surgery preferred in younger women to preserve ovarian function.

Locally advanced disease (Stage IIB–IVA)

Concurrent chemoradiation is the standard of care: cisplatin 40 mg/m² IV weekly × 5–6 weeks, given alongside external beam radiation therapy (EBRT) to the pelvis, followed by intracavitary brachytherapy (HDR or LDR) to boost the cervix.

Cisplatin acts as a radiosensitizer — it does not deliver the full systemic antitumor effect used in metastatic settings, but it enhances radiation-induced DNA damage in tumor cells.

Metastatic and recurrent disease (Stage IVB / recurrence)

• First-line: Cisplatin + paclitaxel + bevacizumab (or carboplatin-based doublet)
• Pembrolizumab: Approved for PD-L1-positive (CPS ≥1) recurrent or metastatic cervical cancer. PD-L1 testing is now routine for advanced disease.
• Cemiplimab: Approved as second-line for recurrent/metastatic disease regardless of PD-L1 status.

Nursing priorities

Post-LEEP patient education

LEEP is performed in the clinic under local anesthesia. Post-procedure nursing education must cover:

• Restrictions × 4 weeks: No tampons, no sexual intercourse, no heavy lifting or vigorous exercise. The cervical wound heals in approximately 4 weeks; disrupting it risks hemorrhage.
• Expected discharge: A brownish-black discharge is expected — this is from the ferric subsulfate (Monsel’s solution) or silver nitrate used to achieve hemostasis, combined with normal healing eschar. Patients should be specifically told to expect this so they are not alarmed.
• Return precautions: Fever >38°C (100.4°F), heavy bleeding (soaking a pad per hour for 2+ hours), or foul-smelling discharge should prompt immediate evaluation.
• Follow-up: Repeat co-testing at 6 months to confirm adequate treatment of CIN 2/3.

Radical hysterectomy nursing care

Preoperative: Bowel prep is surgeon-dependent; DVT prophylaxis (compression devices, LMWH initiation per protocol); informed consent covering urinary dysfunction, sexual function changes, and lymphedema risk. Link to DVT nursing for VTE prophylaxis specifics.

Postoperative priorities:

• Urinary retention: Radical hysterectomy requires extensive dissection around the bladder and ureters, disrupting the autonomic innervation of the detrusor. Urinary retention or impaired bladder sensation is expected and can persist for 3–6 weeks post-operatively. An indwelling Foley catheter is typically maintained for 1–3 weeks; some surgeons perform a voiding trial before discharge with PVR measurement. Nurses must monitor for urinary retention when the catheter is removed — this is a high-yield NCLEX concept.
• Lymphedema risk: Pelvic lymph node dissection removes regional nodes and disrupts lymphatic drainage to the lower extremities. Patients should receive education on compression garment use, skin protection, avoidance of constrictive clothing, and early signs of lymphedema. Full detail is available in the lymphedema nursing reference.
• Wound care: Abdominal or laparoscopic incision surveillance for infection, dehiscence, hematoma. Assess surgical drain output if applicable. See wound assessment for systematic evaluation approach.
• Sexual function: Radical hysterectomy shortens the vaginal vault, alters pelvic anatomy, and can affect arousal and sensation. Proactive sexual health counseling is essential.

Concurrent chemoradiation nursing

Cisplatin nephrotoxicity prevention is the dominant pharmacologic nursing priority. Cisplatin concentrates in renal tubules and causes direct tubular injury; the risk is dose-dependent and cumulative.

Protocol elements:

• Aggressive pre-hydration: Normal saline 1–2 L IV over 2–4 hours before cisplatin infusion
• Post-hydration: Continue IV fluids for several hours after infusion
• Electrolyte supplementation: Magnesium and potassium are wasted by cisplatin-injured tubules; replace prophylactically and monitor levels before each cycle
• Urine output monitoring: Maintain UO ≥100 mL/hr during and for several hours after infusion
• BUN and creatinine: Check before each weekly dose; hold or dose-reduce if creatinine rises
• Nephrotoxic drug avoidance: Hold NSAIDs, aminoglycosides, contrast agents, and other nephrotoxins during treatment

Full management detail for cisplatin-associated acute kidney injury at AKI nursing.

Radiation skin care: The perineum and perianal region fall within pelvic radiation fields. Patients develop radiation dermatitis that can progress to moist desquamation. Nursing management: gentle cleansing with mild soap, avoid friction and heat, moisture barrier creams, no topical products with alcohol, loose cotton clothing.

Vaginal mucositis: Radiation to the cervix and vaginal cuff causes mucositis with friability, pain, and discharge. Sitz baths, perineal hygiene, and gentle vulvar/vaginal care are important. Patients should be warned about expected discharge.

Brachytherapy nursing

Brachytherapy delivers radiation directly to the cervix and upper vagina using an intracavitary applicator (ring-and-tandem or ovoids-and-tandem). It may be administered as low-dose rate (LDR) – requiring inpatient isolation – or high-dose rate (HDR) – delivered in multiple outpatient fractions.

LDR brachytherapy radiation safety (ALARA principles):

• Maintain time as brief as possible — plan care tasks to minimize time at bedside
• Maintain distance — the inverse square law means doubling distance reduces exposure by 75%
• Shielding: Lead-lined room; staff use personal dosimeters
• Visitor restrictions: Pregnant women and children under 18 are excluded from the room entirely while the implant is in place
• An indwelling urinary catheter is placed before applicator insertion and maintained throughout the implant to prevent patient ambulation

HDR brachytherapy: Delivered in fractions over 1–2 days as an outpatient. No radiation safety precautions for nursing staff between fractions; precautions apply during active treatment delivery only.

Vaginal stenosis prevention

Pelvic radiation causes progressive fibrosis of the vaginal walls over months to years. Without intervention, vaginal stenosis develops, leading to dyspareunia, difficulty with future examination, and reduced quality of life.

Vaginal dilator therapy is the standard approach: begin 2–4 weeks after radiation is completed, use dilators with lubricant 3 times per week, progressing to larger sizes over time. Nurses play a central role in normalizing this intervention. Patients often feel embarrassed to discuss it; the framing “this is medical maintenance that preserves comfort and enables future gynecologic exams” often helps.

Psychosocial considerations

Cervical cancer carries a unique psychosocial burden. Because it is sexually transmitted virus-related, patients frequently experience shame, stigma, and guilt — sometimes compounded by partner responses or relationship strain. Nurses should address this directly rather than waiting for patients to raise it.

Fertility loss affects women diagnosed during reproductive years, particularly those requiring radical hysterectomy. Grief responses are legitimate and should be normalized. Refer to reproductive endocrinology early when fertility preservation (e.g., trachelectomy) is being considered.

Body image changes arise from hysterectomy, vaginal changes from radiation, and – when applicable – ostomy or urinary diversion in advanced disease.

Gynecologic cancer NCLEX differentiation

Cervical, endometrial, and ovarian cancers are frequently paired against each other in NCLEX questions. The table below organizes the clinically distinguishing features from the cervical cancer perspective. The ovarian cancer nursing reference provides the same comparison from the ovarian angle.

NCLEX high-yield tips

The following represent the highest-tested concepts for cervical cancer on NCLEX. Each is written as a concise, exam-ready statement.

Tip 1 — HPV strain specificity HPV 16 and 18 are the high-risk oncogenic strains responsible for ~70% of cervical cancers. HPV 6 and 11 cause genital warts but carry no significant malignant potential. Confusing these on NCLEX means a wrong answer.

Tip 2 — Only vaccine-preventable major cancer Cervical cancer is the only major cancer that is preventable through vaccination. This is a standalone NCLEX fact — expect it in priority-setting or health promotion questions.

Tip 3 — Pap smear intervals by age Age 21–29: Pap smear every 3 years (cytology alone). Age 30–65: Pap alone every 3 years OR co-test (Pap + HPV) every 5 years. Memorize the cutoffs — NCLEX tests this directly.

Tip 4 — Screening does not start before 21 Pap smear screening begins at age 21, regardless of when sexual activity began. A 19-year-old who has been sexually active for 3 years does not need a Pap smear. This is a common distractor question.

Tip 5 — Post-LEEP restrictions After LEEP: no tampons, no intercourse, no heavy lifting for 4 weeks. Brown or black vaginal discharge is expected (hemostatic agent). Fever or heavy bleeding → return for evaluation immediately.

Tip 6 — Radical hysterectomy and urinary retention Radical hysterectomy disrupts the autonomic nerves supplying the bladder. Urinary retention is expected and may require an indwelling catheter for 1–3 weeks post-operatively. When the catheter is removed, assess for retention with post-void residuals.

Tip 7 — Cisplatin hydration protocol Cisplatin is nephrotoxic. Aggressive IV hydration before and after infusion is mandatory. Monitor BUN and creatinine before each dose. Withhold nephrotoxic co-medications. This is the primary nursing priority with cisplatin-based chemoradiation.

Tip 8 — Brachytherapy visitor restrictions During LDR brachytherapy: pregnant women and children under 18 are not permitted in the patient’s room. The nurse minimizes time at bedside and maximizes distance when delivering care. Dosimeters are worn.

Tip 9 — Vaginal dilators post-radiation Start vaginal dilator therapy 2–4 weeks after pelvic radiation completes. Prevents vaginal stenosis caused by radiation fibrosis. Use with lubricant 3×/week. This is a long-term survivorship intervention, not optional.

Tip 10 — Stage IIIC and lymph nodes (FIGO 2018) Stage IIIC was added in the 2018 FIGO revision to account for lymph node involvement. Stage IIIC1 = pelvic nodes; Stage IIIC2 = para-aortic nodes. Pre-2018 staging did not include nodal status. NCLEX now reflects the 2018 system.

Tip 11 — Pembrolizumab for PD-L1-positive cervical cancer Pembrolizumab (a PD-1 checkpoint inhibitor) is approved for recurrent or metastatic cervical cancer with PD-L1 expression (CPS ≥1). Immune-related adverse events (irAEs) — pneumonitis, colitis, endocrinopathies — are the primary nursing monitoring priorities. See oncology nursing reference for irAE management frameworks.

Tip 12 — Cervical vs endometrial bleeding Cervical cancer → postcoital bleeding, younger patient, HPV-associated. Endometrial cancer → postmenopausal bleeding, older patient, estrogen-associated. This differentiation appears in NCLEX triage/prioritization scenarios.

Tip 13 — Colposcopy indications Colposcopy is indicated for: HSIL on Pap, ASC-H, ASCUS with positive high-risk HPV co-test, LSIL in certain age groups, or persistent ASCUS on repeat Pap. It is not a screening tool — it is a diagnostic follow-up to an abnormal screen.

Tip 14 — SCC antigen for monitoring SCC antigen (SCC-Ag) is a serum marker used to monitor treatment response and detect recurrence in squamous cell cervical cancer. It is not used for population screening or diagnosis — it lacks sufficient sensitivity and specificity for that purpose.

Tip 15 — Trachelectomy and fertility preservation Radical trachelectomy removes the cervix and upper vagina with pelvic lymph node dissection, while preserving the uterus and ovaries. It is an option for carefully selected patients with Stage IA1–IB1 disease who wish to preserve fertility. Future pregnancy is possible; delivery is by cesarean section.

Tip 16 — Gardasil 9 coverage and limitations Gardasil 9 covers 9 HPV strains (6, 11, 16, 18, 31, 33, 45, 52, 58). It is prophylactic — it prevents infection but does not treat existing HPV infection or reverse CIN. Administering it to someone already HPV-positive still provides protection against the other covered strains.

Tip 17 — Hydronephrosis in Stage IIIB Lateral tumor extension to the pelvic sidewall compresses the ureters, causing hydronephrosis. FIGO Stage IIIB includes hydronephrosis regardless of tumor size. The nurse monitors urine output, creatinine, and signs of acute kidney injury. Ureteral stenting may be required.

Summary: priority nursing actions by treatment phase

Related references

Cervical cancer nursing connects to several broader clinical domains covered in depth elsewhere on this site:

• Oncology nursing reference — chemotherapy safety, hazardous drug handling, oncologic emergency recognition, and extravasation management
• Ovarian cancer nursing — gyn-oncology cluster neighbor; FIGO staging comparison, surgical debulking, and BRCA genetics
• DVT nursing — VTE risk is significant post-pelvic surgery and during immobility from brachytherapy implant
• AKI nursing — cisplatin nephrotoxicity mechanism, hydration protocols, and renal monitoring in the oncology setting
• Lymphedema nursing — pelvic lymph node dissection as a primary lymphedema risk factor; compression and skin care protocols
• Wound assessment — systematic post-surgical wound evaluation relevant to radical hysterectomy and trachelectomy recovery